West Pharmaceutical Services (WST) Retained Earnings (2009 - 2026)

West Pharmaceutical Services has disclosed Retained Earnings across 18 years of filings, most recently posting $4.6 billion for Q2 2026.

• In Q2 2026, Retained Earnings rose 11.71% year-over-year to $4.6 billion; the TTM figure through Jun 2026 stood at $4.6 billion (up 11.71% YoY), while the FY2025 annual figure was $4.4 billion, up 10.57% from the prior year.
• Retained Earnings came in at $4.6 billion for Q2 2026 at West Pharmaceutical Services, up from $4.5 billion in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of $4.6 billion in Q2 2026 to a low of $2.6 billion in Q1 2022.
• Average Retained Earnings over 5 years is $3.6 billion, with a median of $3.7 billion recorded in 2024.
• Year-over-year, Retained Earnings surged 31.83% in 2022 and rose 10.51% in 2025.
• Over 5 years, Retained Earnings stood at $3.0 billion in 2022, then advanced by 17.93% to $3.5 billion in 2023, then rose by 12.29% to $4.0 billion in 2024, then climbed by 10.57% to $4.4 billion in 2025, then advanced by 5.7% to $4.6 billion in 2026.
• Per Business Quant data, the three most recent Retained Earnings figures were $4.6 billion in Q2 2026, $4.5 billion in Q1 2026, and $4.4 billion in Q4 2025.